Cipher Pharmaceuticals (CPH) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $12.0M, up 105% year-over-year, driven by strong Canadian portfolio and Natroba sales, with Natroba generating $6.7M and gaining Medicaid preferred status in Illinois.

• Adjusted EBITDA rose 73% to $6.2M, reflecting operational leverage and product mix.

• Net income was $2.6M (EPS $0.10), down from $4.9M (EPS $0.20) year-over-year, mainly due to lower deferred tax benefits.

• Ongoing efforts to launch Natroba in Canada and out-license globally, with active discussions in seven territories.

• Base business revenue and earnings declined year-over-year, but Canadian product sales grew 41%.

Financial highlights

• Total net revenue was $12.0M in Q1 2025, up 105% year-over-year, mainly due to Natroba.

• Licensing revenue fell 72% to $0.7M, impacted by lower shipments and increased generic competition.

• Canadian product portfolio revenue rose 41% to $4.6M; sales volumes grew 46% year-over-year.

• Gross profit rose 90% to $9.1M; gross margin decreased to 76% from 82% due to product mix and fair value adjustments.

• Adjusted EBITDA was $6.2M, up 73% from Q1 2024.

Outlook and guidance

• Expectation of higher Natroba revenues in Q2 and Q3 due to seasonality, with anticipated high single to low double-digit quarterly growth.

• Focus remains on profitability, market share growth for Natroba in the U.S., and global out-licensing.

• Ongoing pursuit of accretive acquisitions and in-licensing opportunities, with a disciplined approach.

• Plans to acquire complementary dermatology products to expand the North American platform.

• Substantial liquidity with $65M growth capital available and a $40M revolving credit facility as of May 8, 2025.